Stockwinners Market Radar for July 02, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:05 EDT Fly Intel: After Hours Movers - HIGHER: Symantec (SYMC), up 22.2% after Bloomberg reported that it is in advanced talks to be acquired by Broadcom (AVGO)... Tesla (TSLA), up 7.2% after reporting Q2 production and deliveries data. LOWER: Usana (USNA), down 16.6% after it provided preliminary Q2 results and lowered its guidance for fiscal 2019... Broadcom, down 4.4% after Bloomberg reported that it is in advanced talks to acquire Symantec.

18:10 EDT U.S. places duties on steel from Vietnam originally made in SK, Taiwan - The U.S. Department of Commerce announced three preliminary affirmative circumvention rulings involving exports of steel products from Vietnam. The circumvention rulings cover certain steel products that are first produced in Korea and Taiwan, which are then shipped to Vietnam for minor processing, and finally exported to the United States as corrosion-resistant steel products and cold-rolled steel. As a result of today's affirmative circumvention determinations, Commerce will instruct Customs and Border Protection to begin collecting cash deposits on imports of corrosion-resistant steel products and cold-rolled steel produced in Vietnam using Korean- or Taiwanese-origin substrate. These duties will be imposed on future imports, and also on any unliquidated entries since August 2, 2018. The applicable cash deposit rates will be as high as 456.23%, depending on the origin of the substrate and the type of steel product exported to the United States. Publicly traded companies in the space include AK Steel (AKS), ArcelorMittal (MT), Nucor (NUE), Steel Dynamics (STLD), TimkenSteel (TMST) and U.S. Steel (X). Reference Link

18:02 EDT Anaplan CEO sells 100,000 common shares - In a regulatory filing, Anaplan president and CEO Frank Calderoni disclosed the sale of 100,000 common shares of the company at a price of $49.7462 per share.

17:40 EDT WestRock urges holders to reject mini-tender offer by TRC Capital - WestRock Company announced that it has received notification of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 3,000,000 shares, or approximately 1.17% of the outstanding common stock of the company as of April 19, 2019. TRC Capital's offer price of $34.80 per share in cash is 4.58% less than the $36.47 closing price of the company's common stock on June 28, 2019, the last trading day before the mini-tender offer commenced, and 6.55% less than the $37.23 closing price of the company's common stock on July 2, 2019. The company said it does not endorse TRC Capital's mini-tender offer and recommends that stockholders do not tender their shares in response to the offer. The offer is at a price below the current market price for WestRock shares and is subject to numerous conditions, including, among others, that there has not been any decrease in the market price of the WestRock shares and that TRC Capital has received proceeds of debt financing sufficient, together with cash on hand, to consummate the offer. The company urges stockholders to obtain current market quotes for their shares, review the conditions to TRC Capital's mini-tender offer, consult with their brokers or financial advisors and exercise caution with respect to this mini-tender offer. The company is in no way associated with TRC Capital, the mini-tender offer or the offer documentation.

17:18 EDT Lockheed Martin awarded $348.22M Navy contract modification - Lockheed Martin has been awarded $348.22M for modification to a previously awarded cost-plus-fixed-fee contract. This modification is for production non-recurring, special tooling and special test equipment in support of low-rate initial production Lot 12 F-35 Lightning II aircraft for the Air Force, Navy, Marine Corps, non-U.S. Department of Defense, or DoD, partners and foreign military sales customers. Work is expected to be completed in August 2022. FY17 aircraft procurement; FY18 and FY19 aircraft procurement; non-U.S. DoD partner and foreign military sales funds in the amount of $348.22M are being obligated at time of award, $17.9M of which will expire at the end of the current fiscal year. This modification combines purchases for the Air Force, Navy, Marine Corps, non-U.S. DoD partners and foreign military sales customers. The Naval Air Systems Command is the contracting activity.

16:38 EDT Alcoa announces planned restart, new labor deal for ABI smelter in Quebec - Alcoa Corporation (AA) announced that the Aluminerie de Becancour Inc. smelter plans to restart curtailed smelting capacity after members of the United Steelworkers union in Quebec, Canada today approved a six-year labor agreement. The smelter, owned by Alcoa and Rio Tinto Alcan Inc. (RIO), has total annual capacity of 413,000 metric tons per year. The restart will begin on July 26, 2019 and is expected to be complete in the second quarter of 2020. Salaried employees had operated one of three potlines during the lockout, until Alcoa announced an additional curtailment of one half of that potline on December 19, 2018. The ABI smelter will recall the approximately 900 unionized employees according to a specific back-to-work protocol, with all of those on lockout back within eight months of the July 26, 2019 restart date. In the second half of 2019, the company expects to record special items associated with restart expenses of between $40M and $50M after-tax, or 22c and 27c per share.

16:34 EDT EnPro acquires Aseptic Group, terms not disclosed - EnPro Industries announced it has acquired The Aseptic Group, a privately-held company which distributes, designs and manufactures aseptic fluid transfer products for the pharmaceutical and biopharmaceutical industries. The Aseptic Group will become part of EnPro's Garlock Family of Companies, a global supplier of high-performance sealing and fluid handling products to process industries. The business was acquired in a cash transaction.

16:31 EDT Neuronetics names Stephen Furlong CFO - Neuronetics announced that Stephen Furlong will become its new Chief Financial Officer and Secretary, replacing Peter Donato, who will be leaving the company after a transition period. Furlong will assume the role of CFO and Secretary effective July 22, 2019. Furlong most recently served as Senior Vice President of Finance and Corporate Secretary at Metabolon, a global player in metabolomics, a powerful phenotyping technology for advancing biomarker discovery, diagnostic testing and precision medicine. "We are very excited to have Steve join Neuronetics as CFO. Steve brings valuable and highly relevant financial leadership experience with fast growing companies in the medical technology industry to Neuronetics and will be a valuable addition to the senior management team as we look to continue to drive the adoption of NeuroStar Advanced Therapy and expand our market leadership position," said Chris Thatcher, President and Chief Executive Officer of Neuronetics. "I would like to thank Peter for all of his contributions to Neuronetics and wish him all the best going forward. During his nearly three years with the Company, Peter played an integral part in our IPO and was instrumental in growing, scaling and transitioning Neuronetics into a successful public company."

16:21 EDT Tesla Tesla produces 72,531 Model 3, delivers 77,550 Model 3 in Q2

16:20 EDT Tesla produces 87,048 vehicles, delivers 95,200 vehicles in Q2 - In Q2, Tesla achieved record production of 87,048 vehicles and record deliveries of approximately 95,200 vehicles. In addition, the company said, "we made significant progress streamlining our global logistics and delivery operations at higher volumes, enabling cost efficiencies and improvements to our working capital position. Orders generated during the quarter exceeded our deliveries, thus we are entering Q3 with an increase in our order backlog. We believe we are well positioned to continue growing total production and deliveries in Q3." Customer vehicles in transit at the end of the quarter were over 7,400. Due to the order-to-VIN matching process it described in the Q1 2019 Shareholder Letter, which it extended to Model S and Model X in Q2 to improve process efficiency, this metric has become less relevant. As a result, Tesla does not plan to disclose the customer vehicles in transit metric going forward.

16:10 EDT IntriCon repositions hearing aid sales in UK through new distribution pact - IntriCon announced it has entered into a distribution agreement with Puretone, a Rochester, UK-based hearing health company with operations in more than 75 countries. Under the terms of the agreement, Puretone will distribute IntriCon branded hearing aids into the National Health Service system on the Company's behalf. Additionally, IntriCon completed the sale of its PC Werth accessory business assets to Warner Tech-care UK LTD, a subsidiary of US based Warner Tech-care LLC. Warner will continue to sell the accessories and services under the PC Werth brand names in the region. In connection with the distribution agreement and sale of assets, IntriCon ceased all production and direct sales activities at its UK Limited subsidiary, effective June 28, 2019. The closure is expected to provide the Company with a cost reduction of approximately $1.0 million annually. "We are delighted to partner with Puretone. They are a well-respected, global hearing health provider that has a proven track record for reaching the UK's substantial customer base," said Mark Gorder, President and Chief Executive Officer. "Importantly, this shift from direct sales to a distribution model in the UK not only provides us with a reduced cost structure but enables us to better focus our resources on our value-based hearing healthcare opportunities, most notably the large emerging OTC hearing aid market in the US."

16:06 EDT Akero announces dosing of first patient in Phase 2a clinical study of AKR-001 - Akero Therapeutics announced the dosing of the first patient in its Phase 2a clinical study of AKR-001, a novel FGF21 analog, for the treatment of NASH. The Phase 2a BALANCED study is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging trial in biopsy-confirmed patients with NASH. Up to 80 patients are expected to be randomized to receive weekly subcutaneous dosing of AKR-001 or placebo for up to 16 weeks, with safety and tolerability followed through week 20. The primary efficacy endpoint for the study is absolute change from baseline in hepatic fat fraction measured by Magnetic Resonance Imaging - Proton Density Fat Fraction Week 12.

16:04 EDT MarketAxess announces monthly training volume of $182.9B for June - MarketAxess announced total monthly trading volume for June of $182.9B, consisting of $91.3B in U.S. high-grade volume, $86.5B in other credit volume and $5B in liquid products volume.

16:02 EDT Veradigm partners with ACC to develop research network - Veradigm, an Allscripts business unit dedicated to simplifying healthcare with data driven health insights and technologies to help manage costs and improve health outcomes, announced that it has partnered with the American College of Cardiology to power the next generation of real-world research on behalf of cardiovascular disease and diabetes patients around the world. As part of this partnership, Veradigm will operate the PINNACLE Registry, which focuses on coronary artery disease, hypertension, heart failure, atrial fibrillation and diabetes in the outpatient setting, and the Diabetes Collaborative Registry, the first global, cross-specialty clinical registry designed to track and improve the quality of diabetes and metabolic care across the primary care and specialty care continuum from the American College of Cardiology. PINNACLE and Diabetes Collaborative Registries will extend Veradigm's EHR-enabled ambulatory research network to create a large-scale chronic disease network with more than 250,000 clinicians and 150 million patients including Veradigm partner data sets in the United States. In addition to integrating Veradigm's technology, data and analytic capabilities with the ACC's PINNACLE Registry and Diabetes Collaborative Registry, the partnership will leverage Veradigm's large specialist and primary care provider network, utilizing its electronic health record platforms to bring ACC's clinical guidelines, decision pathways, education and wealth of provider and patient engagement tools to the point of care.

15:57 EDT Amber Road trading resumes

14:23 EDT RBF Capital reports 5.98% passive stake in Asta Funding - In a regulatory filing, RBF Capital disclosed a 5.98% stake in Asta Funding, which represents 400,000 shares of common stock. The filing does not allow for activism.

13:18 EDT European Council appoints new EU leaders, nominates Lagarde for ECB - The European Council elected Charles Michel as President of the European Council for the period from 1 December 2019 until 31 May 2022. The European Council also welcomed the decision of the Heads of State or Government of the Member States whose currency is the euro to appoint Charles Michel as President of the Euro Summit, for the same term of office. The European Council adopted the decision proposing Ursula von der Leyen to the European Parliament as candidate for President of the European Commission. The proposed candidate will need to be elected by the European Parliament by a majority of its component members. The European Council also considered Josep Borrell Fontelles to be the appropriate candidate for High Representative of the Union for Foreign Affairs and Security Policy. The formal appointment of the High Representative by the European Council requires the agreement of the President-elect of the Commission. The European Council also considered Christine Lagarde to be the appropriate candidate for President of the European Central Bank. The European Council will take a formal decision on the appointment on the basis of a Council recommendation, after having consulted the European Parliament and the ECB's Governing Council. The mandate for the President of the European Central Bank is for 8 years non-renewable. Reference Link

13:01 EDT Deluxe expands existing partnership with Salesforce - Deluxe Corporation (DLX) announced an expanded agreement with Salesforce (CRM) to accelerate Deluxe's go-to-market strategy and improve customer engagement by getting a 360-degree view of customers across its entire business. In partnership with Salesforce Success Cloud advisory services, Deluxe is consolidating its customer service, direct and indirect sales, digital commerce, analytics and marketing systems onto a single CRM platform. This will offer Deluxe unprecedented insight into its diverse customer base and the ability to cross-sell and up-sell products and services best suited to each customer. As part of this long-term agreement, Deluxe and Salesforce will also collaborate to provide mutual small business customers with innovative product solutions, including Deluxe's growing portfolio of Small Business Solutions and Salesforce Essentials. More details on the partnership will be communicated in the Fall during Deluxe's appearance as a speaker at Salesforce's annual event, Dreamforce, the world's largest software conference.

12:01 EDT Volkswagen reports June U.S. sales up 10% to 31,725 units - Volkswagen of America reported June sales rose 10% from the prior year to 31,725 units, calling the month Volkswagen of America's "best June since 2013." Reference Link

11:02 EDT Seelos Therapeutics receives Notice of Allowance for a U.S. patent for SLS-005 - Seelos Therapeutics announced that they have received a Notice of Allowance from the United States Patent and Trademark Office for Seelos' U.S. Patent Application for SLS-005 for treating Friedreich Ataxia. SLS-005 already has orphan indication for Spinocerebellar Ataxia and Seelos is currently developing SLS-005 for Sanfilippo syndrome followed by the OPMD indication.

10:57 EDT EQT's independent nominees urge shareholders to vote for all 12 nominees - EQT Corporation announced that the independent nominees on both the company's and the Toby Rice Group's slates sent an open letter to shareholders. The letter read in part, "As the independent director nominees supported by both EQT and the Toby Rice Group, we feel it is important to communicate directly to shareholders in advance of the upcoming Annual Meeting. We share the frustration some have expressed regarding the old EQT and the Company's share price performance. It is our belief that EQT's 12 director nominees are best suited to oversee EQT's operations and continue its transformation into a free cash flow leader. If elected, the new EQT Board will be one of the most, if not the most, experienced and diverse boards in the E&P industry; nine of 12 directors will have direct oil and gas industry upstream experience, and nine of 12 will have been elected since 2017...Over the last six months, the EQT team has significantly improved EQT's financial and operating results while reducing costs. The Company has delivered three consecutive quarters of strong performance and is on track to achieve $300M to $400M of adjusted free cash flow in 2019 and at least $3B through 2023. We have been impressed with management's progress in the currently challenging operating environment. While we are pleased with recent results and believe that management has solved the legacy issues of the old EQT, as directors we will demand that the management team build on and accelerate its progress... EQT has been through enormous disruption over the last two years, from the numerous complex transactions to facilitate the spin-off of Equitrans Midstream Corporation to substantial turnover in the C-suite. In seven short months, the new EQT management team has implemented a profound cultural shift across the organization with an emphasis on accountability, collaboration and transparency. We believe this management team's performance over the last three quarters has earned it the chance to show that it can achieve the continued turnaround we seek. Employees are now energized and passionate about the new EQT and committed to doing their part to drive strong results for shareholders. We believe that exposing the Company to further turnover, disruption and execution risk would be counterproductive. However, we are fully cognizant that our role as independent directors is to hold management accountable for the Company's performance. If this management team fails to deliver, we are committed to finding the most highly qualified and experienced candidates for those roles."

10:48 EDT Middlesex Water announces retirement of COO Richard Risoldi - Middlesex Water Company announced that Richard Risoldi, SVP, operations & COO retired effective July 1, 2019. The company reported several executive leadership changes in October 2018 in connection with its succession plans. The following executives, G. Christian Andreasen, Georgia Simpson and Robert Fullagar have been named VP of the company effective July 1, 2019 and will join the company's Executive Committee. G. Christian Andreasen has been named VP, enterprise engineering. This role will bring the engineering and all related elements of capital planning and execution for all companies in the Middlesex Water Company enterprise under a single management structure. Georgia Simpson has been named VP, information technology. This role reflects the expanded prominence of information technology in the company's strategy, business processes and risk profile.Robert Fullagar has been named VP, operations. This role assumes responsibility for the Production and Distribution functions as well as Wastewater Collection and Treatment functions enterprise-wide.

10:32 EDT Toyota reports June U.S. sales down 3.5% to 202,352 vehicles - Toyota Motor North America reported June sales of 202,352 vehicles, a decrease of 3.5% on a volume basis and an increase of 0.3% on a daily selling rate, or DSR, basis versus June 2018. Toyota division posted June sales of 179,305 vehicles, down 3.5% on a volume basis and up 0.2% on a DSR basis. Lexus division posted June sales of 23,047 vehicles, down 3.0% on a volume basis and up 0.8% on a DSR basis.

10:13 EDT Bayer treatment of glioblastoma multiforme granted orphan status - Bayer's treatment of glioblastoma multiforme was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

10:11 EDT AveXis treatment of Amyotrophic Lateral Sclerosis granted orphan status - AveXis' treatment of Amyotrophic Lateral Sclerosis was granted orphan status by the FDA, according to a post to the agency's website. Reference Link

10:00 EDT Cars.com rises 5.3% - Cars.com is up 5.3%, or $1.04 to $20.91.

10:00 EDT Maxar Technologies rises 6.8% - Maxar Technologies is up 6.8%, or 54c to $8.46.

09:47 EDT Acuity Brands falls -9.7% - Acuity Brands is down -9.7%, or -$13.64 to $127.38.

09:47 EDT Spirit Realty rises 4.2% - Spirit Realty is up 4.2%, or $1.78 to $44.13.

09:47 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 6.2% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 6.2%, or $3.23 to $54.83.

09:38 EDT Wheeler REIT reduces KeyBank line of credit carried balance - Wheeler Real Estate Investment Trust (WHLR) announced that it has made further progress in reducing the balance on the Company's KeyBank line of credit. The Company obtained a 10-year fixed rate term loan for $16.5M at an interest rate of 4.28%, which is approximately 62 bps below the current interest rate on the Company's KeyBank line of credit as of June 28, 2019. The new loan is secured by the 297,950 square-foot, Kroger-anchored shopping center, The Village at Martinsville located in Martinsville, Virginia, which was previously encumbered on the Company's KeyBank line of credit. As a result, the Company has effectively extended and better laddered its debt maturities while reducing its KeyBank line of credit down to $34.3M.

09:36 EDT Facebook fined EUR2M for violating German transparency law - Germany's Federal Office of Justice has issued a fine notice against Facebook Ireland Limited, as the company violated the provisions of the Network Enforcement Act when publishing the Transparency Report for the first half of 2018 . In the fine, the BfJ complains in particular that in the published report, the number of complaints received about illegal content is incomplete. This creates a distorted picture in the public about the extent of illegal content and the way the social network deals with them. The BfJ has imposed a fine of two million euros.

09:31 EDT FCA US reports June sales up 2% to 206,083 vehicles - FCA US LLC reported its "best June in 14 years" as total sales climbed 2% to 206,083 vehicles, driven by Ram pickup trucks which had its highest month of sales since the brand was detached from Dodge and launched as a standalone division in 2009. Sales of Ram pickups for June rose 56% to 68,098 vehicles. For the quarter, Ram pickup truck sales finished at 179,454 vehicles. Overall, June retail sales for FCA US hit the highest level in 18 years with 156,588 vehicles sold. Fleet sales totaled 49,495 vehicles and accounted for 24% of total sales.

09:28 EDT MJ Freeway announces new clients in Europe, opens Colombian office - MJ Freeway, a wholly owned subsidiary of Akerna, expands further into Europe by serving clients in two additional countries, Italy and Macedonia. Macedonia is one of the few countries in the world to approve medical cannabis for cultivation and export. Italy has significantly increased its hemp production to serve its growing domestic market for industrial products and infusing in cosmetics and other consumer goods. As a result of the expansion into Italy and Macedonia, MJ Freeway has increased its footprint to five European countries including Spain, Switzerland and Denmark. The new clients are cultivation operators who have chosen to run their businesses with MJ Platform, an enterprise resource planning compliance and inventory management technology platform. MJ Freeway has recently opened a Medellin, Colombia office to serve its growing footprint in South America. Clever Leaves, a MJ Freeway client, is the first Colombian company authorized to export cannabis into Canada. In addition to Clever Leaves, MJ Freeway's clients in Colombia are enterprise-scale, multi-national organizations poised to capitalize on the growing global market with approved export licenses.

09:25 EDT Generex engages Donohoe Advisory to assist with uplisting - Generex Biotechnology announced that Generex has engaged Donohoe Advisory Associates in connection with its efforts to seek a listing for its common shares on a national securities exchange.

09:23 EDT Glaxo, Pfizer JV receives conditional approval from South Africa regulator - The planned joint venture between GlaxoSmithKline (GSK) and Pfizer (PFE) has received conditional approval from South Africa's Competition Commission, the regulator said in a statement. Although the deal is not likely to reduce competition, it said the deal will impact local manufacturers of pharmaceuticals for Pfizer. To address those concerns, the regulator suggested the companies continue using Spechpharm Holdings for a period of three years.

09:17 EDT Bassett Furniture CEO says company is 'mobilized on multiple fronts' - "In reaction to the challenging big ticket retail environment, we are mobilized on multiple fronts," said CEO Rob Spilman. "There is no doubt that more aggressive use of discounts and credit promotions increasingly characterize today's furniture retail space. We successfully employed our variation of these tactics over the three week Memorial Day promotion. Going forward, we will use a mix of newly crafted promotional messages and consumer financing designed to more overtly emphasize the value of our products. In concert, we have strengthened our long standing '30 Days in the Home' on custom furniture with the addition of a '14 Days in the Home' message on a series of wood and upholstery items. Furthermore, as we mentioned after the first quarter, we are expanding our opening price point merchandise assortment to expand our reach with value conscious consumers. Coupled with our digital engagement strategy, we are encouraged by the page views that the new value oriented merchandise has generated. Again, although we remain committed to our design makeover and custom furniture strategy, we have concluded that a layer of opening price point merchandise with a compelling delivery promise will bring a new customer to Bassett. We believe that our manufacturing efficiencies and our supply chain will allow us to pursue these tactics without sacrificing our wholesale and retail gross margins. Over 75% of Bassett branded products shipped from an American factory in the quarter and we will leverage our ability to manufacture and deliver our products with heightened speed and value."

09:10 EDT Washington Trust provides $11.8M to Waterford Parc for apartment complex - Washington Trust's Commercial Real Estate Group recently provided $11.8M to Waterford Parc for the construction of a 72-unit apartment complex in Waterford, Connecticut. Located just off Waterford's retail corridor of Route 1, the property is a low-rise development containing three buildings, each of which is three stories in height. The apartments include 36 one-bedroom units and 36 two-bedroom units, each ranging in size from 845 to 1,140 square-feet. The property also features a large clubhouse, fitness center, recreation area, and in-unit washers and dryers.

09:07 EDT ACNB Corp to acquire Frederick County Bancorp for $38.20 per share - ACNB Corporation (ACNB) announced the execution of a definitive agreement whereby Frederick County Bancorp (FCBI), headquartered in Frederick, MD, will be merged with and into an ACNB acquisition subsidiary and, as soon as possible thereafter, Frederick County Bank, FCBI's wholly-owned subsidiary, will merge with and into ACNB Bank. Frederick County Bank operates five bank center locations in the Frederick, MD, area. Established in 2001, Frederick County Bank is a full-service community bank serving businesses, individuals, and community organizations. As of March 31, 2019, FCBI had total assets of $442.4M, total deposits of $372.3M, and total loans of $341.7M. With the consummation of the acquisition, ACNB Bank will operate former Frederick County Bank locations in the Frederick County market as "FCB Bank, A Division of ACNB Bank". One director from FCBI will join the boards of directors of ACNB and ACNB Bank, respectively. In addition, the other directors of FCBI will have the opportunity to serve on a regional advisory board to be established for the Frederick County market. Pursuant to the terms of the definitive agreement, FCBI shareholders will receive 0.9900 share of ACNB common stock for each share of FCBI common stock that they own as of the closing date. Based on the market close on July 1, 2019, the transaction is valued at $60M or $38.20 per share. The transaction is intended to qualify as a tax-free reorganization for federal income tax purposes. Based on the financial results as of March 31, 2019, the combined company would have pro forma total assets of $2.2B, total deposits of $1.8B, and total loans of $1.7B. Once the acquisition is complete, ACNB will have 34 community banking offices in Pennsylvania and Maryland---offering a full range of integrated financial services including banking, trust, retail brokerage, and insurance. Further, as this is a market expansion transaction, ACNB plans to retain many of FCBI's employees, specifically in the areas directly serving customers such as community banking and lending. The transaction has been unanimously approved by the boards of directors of both companies. It is subject to FCBI shareholder approval, ACNB shareholder approval, regulatory approvals, and other customary closing conditions. Currently, the transaction is expected to close in the fourth quarter of 2019 or the first quarter of 2020, after all such conditions are met.

09:04 EDT UnitedHealth announces Atlanta HBCU partnership, $8.25M investment - UnitedHealth Group and the Atlanta University Center Consortium, or AUCC, "the oldest and largest consortium of historically black colleges and universities," or HBCUs, are partnering on a new initiative to prepare students to meet the growing demand in the marketplace for data analytics experts. The five-year, $8.25M investment by UnitedHealth Group is part of an ambitious collaboration with AUCC and its membership: Clark Atlanta University, Morehouse College, Morehouse School of Medicine and Spelman College. The investment will fund the launch of the AUCC Data Science Initiative, which will offer technical classes for students who want to specialize in data science or learn data analysis to give them a competitive edge when they look for jobs in their field of study. "The partnership comes as the number of job openings in the United States for data professionals is projected to reach more than 2.7M by 2020, according to a national study."

09:03 EDT Heico subsidiary acquires assets of Bretigny-sur-Orge - HEICO announced that its Buc, France-based 3D PLUS subsidiary acquired substantially all of the assets and business of Bretigny-sur-Orge, France-based BERNIER, SAS in an all cash transaction. 3D PLUS is part of HEICO's Electronic Technologies Group. No further financial details were disclosed, but HEICO expects the acquisition to be accretive to its earnings within the first 12 months after closing. The business will continue to operate under the BERNIER name and in its current engineering and production facility located in Bretigny-sur-Orge. Further, BERNIER, 3D PLUS and HEICO stated that they do not expect any staff turnover from among BERNIER's approximately 40 talented Team Members to result from the acquisition. 3D PLUS and HEICO were advised in the transaction by Thibaut de Monclin of investment banking firm Oaklins France and the law firm Archers, both in Paris.

09:01 EDT Dassault Aviation acquires business aviation activities from RUAG - Dassault Aviation and RUAG announced the acquisition by Dassault Aviation of the maintenance and FBO activities of RUAG in Geneva and Lugano. "The acquisition of the business aviation activities of RUAG is part of our strategy to develop a worldwide MRO network of excellence and will allow Dassault Aviation to reinforce its footprint in Switzerland. RUAG has been a long-time partner of Dassault Aviation as an authorized Falcon service center. This acquisition will consolidate our network in Geneva and Lugano. Both Geneva and Lugano FBO activities will complement the full range of services offered by Dassault Aviation in Switzerland", declared Eric Trappier, Chairman and CEO of Dassault Aviation.

08:57 EDT Deutsche Balaton, DELPHI increase bid for Biofrontera shares to EUR 8.00 - Deutsche Balaton Biotech AG and DELPHI Unternehmensberatung announced yesterday that they decided to increase their offer price for the currently ongoing voluntary public partial purchase offer for up to 500,000 shares of Biofrontera AG. The bidders will now offer Biofrontera shareholders a cash consideration of EUR 8.00 per Biofrontera share. "The increase in the offer takes account of the recent rise in stock market price. The increased consideration now not only exceeds the historical stock exchange prices from the time before the decision of the bidders to submit the partial purchase offer, but also the current stock exchange price. In addition, the increased consideration also exceeds the consideration offered in the competing offer of Maruho Deutschland GmbH by approximately 11%," they explained.

08:48 EDT Arizona Governor withdraws incentives to Nike after Betsy Ross shoe cancelled - In a series of tweets, Arizona Governor Doug Ducey stated: "Today was supposed to be a good day in Arizona, with the announcement of a major @Nike investment in Goodyear, AZ...Instead of celebrating American history the week of our nation's independence, Nike has apparently decided that Betsy Ross is unworthy, and has bowed to the current onslaught of political correctness and historical revisionism. It is a shameful retreat for the company. American businesses should be proud of our country's history, not abandoning it. Nike has made its decision, and now we're making ours. I've ordered the Arizona Commerce Authority to withdraw all financial incentive dollars under their discretion that the State was providing for the company to locate here." Reference Link

08:47 EDT Acuity Brands CEO says focus for 2020 is 'to garner top-line growth' - CEO Vernon Nagel commented, "Our focus for fiscal 2020 and beyond is to garner top-line growth driven primarily by outperforming the growth rates of the markets we serve through execution of our previously announced growth strategies, improvement in the mix of products and solutions sold as we execute our tiered solutions strategy, and leveraging our fixed cost infrastructure to achieve targeted incremental margins to improve our overall profitability. We continue to believe the lighting and lighting-related industry as well as building management systems have the potential to experience solid growth over the next decade, particularly as owners and users of lighting equipment and buildings continue to see the potential to transform those investments into strategic assets by deploying our distinctive solutions. We believe we are uniquely positioned to fully participate in this exciting industry."

08:39 EDT Chanticleer Holdings completes Rights Offering for gross proceeds of $6.1M - Chanticleer Holdings announced that it has closed its previously announced Rights Offering, which expired on June 28, 2019. Chanticleer received subscriptions for an aggregate of 6,084,853 shares of common stock through the exercise by its record holders of basic and over subscription rights at a price of $1.00 per share. Gross proceeds to Chanticleer of approximately $6,084,853.00 include $3,075,000.00 subscribed through the reduction of outstanding debt obligations. Chanticleer intends to use the net proceeds of the Rights Offering for general corporate purposes and is in discussions with the target to restructure the acquisition proposal. After the Rights Offering, Chanticleer will have an aggregate of 10,023,876 shares of common stock issued and outstanding. Investors who participated in the Rights Offering should expect to see shares in their account within the next three business days.

08:34 EDT ADDvantage closes sale of cable TV segment for $10.3M - ADDvantage Technologies announced the closing of the sale of its Cable TV segment on July 1, 2019 to Leveling 8, which purchased all of the outstanding shares and limited liability company membership interests of the Company's Cable TV segment for a total purchase price of $10.3M. subject to certain post-closing adjustments. Leveling 8 is a company owned 100% by David E. Chymiak, the Company's CTO, president of Tulsat, substantial ADDvantage shareholder and a member of its Board of Directors. The purchase price consists of $3.9M of cash, less $2.1M of cash previously received from the sales of the ComTech facility in March 2019 and the NCS facility in June 2019, and a $6.4M promissory note bearing interest at 6% per annum. The note will be paid over five years and is personally guaranteed by David E. Chymiak. As previously announced in its press release dated March 29, 2019, the Company closed the sale of its Warminster, Pennsylvania facility, which houses the Company's NCS Industries business within the Cable TV segment, to David Chymiak, LLC, a company controlled by David Chymiak, on June 14, 2019 for a purchase price of $0.7M. This amount was deducted from the final proceeds received from the sale of the Cable TV Segment. The sale proceeds will allow ADDvantage Technologies to commit more capital and resources to its expansion strategy in the Wireless Infrastructure Services and Telco segments.

08:31 EDT Criteo enters partnership with Custora - Custor announced its strategic partnership with Criteo. The partnership will leverage Custora's leading platform to acquire and retain customers with Criteo's world-class capabilities to deliver real-time, personalized dynamic ads.

08:24 EDT Eros International reports outstanding interest payments of EIML were paid - Eros International offered the following update: The company reports that outstanding interest payments of the company's Indian operating subsidiary, EIML, that caused a recent ratings downgrade by CARE have been paid by EIML. The company is working with CARE in an attempt to restore its previous investment grade rating, with the full support of its existing banking consortium. In addition, the company reiterates that the recent withdrawal of its Moody's rating was at the company's request given that it does not have any outstanding public institutional bonds.

08:19 EDT BrainStorm initiates third clinical site for Phase 2 progressive MS study - BrainStorm Cell Therapeutics announced that the Company has contracted with the Keck School of Medicine of The University of Southern California and its academic medical center, Keck Medicine of USC as the third clinical study site for the Company's Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with progressive Multiple Sclerosis. The study will be directed at USC by Daniel Pelletier, MD, Professor of Neurology, Eric and Peggy Lieber Chair in Neurology, Vice Chair, Vice Chair, Clinical Research, Department of Neurology; and Division Chief, Neuro-Immunology and USC Multiple Sclerosis Center.

08:17 EDT Sunworks to construct 416 kW solar project for Avenales Cattle Company - Sunworks announced a new 416 kW solar power construction project for Avenales Cattle Company, located in Shandon, California. Construction of the new $800,000, 416kW ground-mount system project is expected to commence in the fourth quarter this year.

08:14 EDT Calithera initiates Phase 1/2 trial of telaglenastat with Pfizer's palbociclib - Calithera Biosciences (CALA) announced treatment of the first patient in a Phase 1/2 open-label clinical trial of the glutaminase inhibitor telaglenastat in combination with Pfizer's (PFE) CDK 4/6 inhibitor palbociclib, also known as Ibrance. The study will evaluate the safety and anti-tumor activity of telaglenastat plus palbociclib in patients with KRAS-mutated colorectal cancer and KRAS-mutated non-small cell lung cancer. Telaglenastat is designed to block glutamine consumption in tumor cells. Genetic alterations, such as mutations in KRAS, can cause cancer cells to increase metabolism of glutamine. In preclinical studies with KRAS-mutated cancer models, telaglenastat showed synergistic antitumor effects when used in combination with CDK4/6 inhibitors, such as palbociclib, enhancing cell cycle arrest and blocking cancer cell proliferation. The Phase 1/2 clinical trial will evaluate the safety and anti-tumor activity of the telaglenastat plus palbociclib combination in patients with locally advanced/metastatic KRAS-mutated CRC and KRAS-mutated NSCLC that are refractory or intolerant to standard therapies.

08:11 EDT Sonim added to Russell 3000 Index - Sonim was added to the broad-market Russell 3000 Index at the conclusion of the annual reconstitution of Russell indexes effective after the U.S. market opened on July 1.

08:10 EDT Facebook fined EUR2B for violating German transparency law - Germany's Federal Office of Justice has issued a fine notice against Facebook Ireland Limited, as the company violated the provisions of the Network Enforcement Act when publishing the Transparency Report for the first half of 2018 . In the fine, the BfJ complains in particular that in the published report, the number of complaints received about illegal content is incomplete. This creates a distorted picture in the public about the extent of illegal content and the way the social network deals with them. The BfJ has imposed a fine of two million euros.

08:07 EDT Rice Team encourages EQT shareholders to vote WHITE universal proxy card - Toby Z. Rice and the other members of the Rice Team, shareholders of EQT, wrote an open letter to encourage their fellow EQT shareholders to vote on the Rice Team's WHITE universal proxy card to elect all seven of the Rice Team's nominees and the five EQT nominees supported by the Rice Team. EQT's annual meeting is scheduled to be held on July 10.

08:04 EDT Amber Road trading halted, news dissemination

08:04 EDT Target Hospitality announces acquisition of community from ProPetro Holding - Target Hospitality (TH) announced the acquisition of a 168-room community located in Midland, TX from ProPetro Holding (PUMP), expanding its presence in the Permian Basin to 19 communities. The acquisition strengthens Target Hospitality's relationship with ProPetro. In conjunction with the transaction, the Company signed a long-term, exclusive network contract with ProPetro, including a long-term agreement for the entire Midland community. This will provide ProPetro with access to Target Hospitality's full suite of turnkey services at the Midland location as well as across the Company's proprietary Permian Basin lodging network. The transaction closed on July 1.

08:02 EDT Mogo Finance sells 5.25% interest in Wekerloo Developments for $2.1M book value - Mogo Finance announced the sale of its 5.25% interest in Wekerloo Developments for book value of $2.1M to an arms' length buyer. Wekerloo is a private commercial real estate holding company with properties in Waterloo, Ontario and was one of the investments in the $24M investment portfolio the company acquired through the recently completed business combination with Difference Capital. The sale also included the assignment of a two-year option to purchase an additional 5% interest in Wekerloo.

07:40 EDT Incyte, Zai Lab enter into collaboration, license agreement for INCMGA0012 - Incyte (INCY) and Zai Lab Ltd. (ZLAB) announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. Under the terms of the agreement, Zai Lab will pay Incyte $17.5M up front, and Incyte is eligible to receive up to an additional $60M in potential development, regulatory and commercial milestones, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics, Inc. Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. Incyte will retain an option to assist in the promotion of INCMGA0012 in Zai Lab's licensed territories.

07:37 EDT CME Group reports June ADV up 29% to 23.1M - CME Group reached average daily volume, or ADV, of 20.9M contracts during Q2, up 14% from Q2 2018 and the second-highest quarterly volume on record. June volume averaged 23.1M contracts per day, up 29% from June 2018. Open interest at the end of June was 141M contracts, up 22% from year-end 2018 and up 23% from June 2018.

07:35 EDT Incyte and Zai Lab announce collaboration and license agreement for INCMGA0012 - Incyte (INCY) and Zai Lab (ZLAB) announced that the companies have entered into a collaboration and license agreement for the development and commercialization of INCMGA0012, an investigational anti-PD-1 monoclonal antibody, in Greater China. Under the terms of the agreement, Zai Lab will pay Incyte $17.5M up front, and Incyte is eligible to receive up to an additional $60M in potential development, regulatory and commercial milestones, as well as tiered royalties from the low to mid-twenties, with Incyte responsible for all royalties and pass-through payments to its licensing partner, MacroGenics, Inc. Zai Lab will receive the rights to develop and exclusively commercialize INCMGA0012 in hematology and oncology in mainland China, Hong Kong, Macau and Taiwan. Incyte will retain an option to assist in the promotion of INCMGA0012 in Zai Lab's licensed territories. The transaction is effective immediately upon the execution of the collaboration and license agreement.

07:31 EDT Canadian National investing $210M in North Vancouver rail capacity - CN announced that western Canadian grain movement in the month of June exceeded 2.3 million metric tonnes, compared to the three year average of 1.80 MMT and June 2018's result of 1.99 MMT. The cumulative total of tonnage moved for the 2018-19 crop year is on record pace at 25.5 MMT, or one million metric tonnes ahead of the previous record pace, despite the restrictions on Canadian exports to China. "Our dedication to providing outstanding service for the Canadian economy contributes to Canada's reputation as a strong and stable supply chain provider," said CEO JJ Ruest. "We are investing $210M in rail capacity in North Vancouver to support the expanding coal and grain export terminals and to further encourage the growth of natural resources export supply chains." "Our investments and dedicated grain team focused our efforts onto what is going to be a record year," said Allen Foster, vice president of Bulk at CN. "We are optimistic that the strong pace of shipments we've seen in June takes us through to the end of the crop year and we can build on our record shipment pace."

07:27 EDT James E Wagner gets Health Canada approval for additional production capacity - James E. Wagner Cultivation announced that on June 28, 2019, it received approval of a licence amendment from Health Canada, permitting it to grow cannabis in additional flowering rooms at the Corporation's flagship facility, JWC 2, located at 530 Manitou Drive in Kitchener, Ontario. The newly approved flowering rooms will add approximately 11,000 sq. ft., resulting in a total of nearly 22,000 sq. ft. of flowering space at JWC 2. The additional flowering rooms approved by Health Canada are the result of the previously press released Phase 2 construction of JWC 2. At full-scale, JWC 2 will measure 345,000 sq. ft. and is expected to be fully equipped with the Corporation's GrowthSTORM Dual Droplet System. The proprietary GrowthSTORM(TM) Dual Droplet(TM) System is a cultivation system that uses two separate nutrient solutions, delivered to the plant's root system through two distinct channels, all housed within a single enclosure. The JWC team has already completed a variety of preparations designed to populate the new Phase 2 flowering rooms with plants shortly after receiving this Health Canada approval.

07:22 EDT Reebonz Holding expands 'Sell to Reebonz' to five new markets - Reebonz Holding Limited announced that it has expanded its recently launched "Sell to Reebonz" service to five new markets: Malaysia, Indonesia, Hong Kong, Taiwan, and Australia. The "Sell to Reebonz" service makes selling as easy as buying and gives all luxury consumers an easy and trusted way of selling their pre-owned designer products.

07:19 EDT Emerald Health's JV launches endocannabinoid-supporting health supplement - Emerald Health Therapeutics, through its joint venture Emerald Health Naturals, has introduced a cannabis-free herbal and botanical endocannabinoid-supporting health supplement product line in Canada. EHN's Endo products, which do not contain cannabis or its derivatives, aim to support the endocannabinoid system to help maintain equilibrium in the body and are already available in over 200 natural health food stores across Canada. The Endo product line includes Endo Brain, Endo Sleep, Endo Calm, Endo Bliss, Endo Inflame and Endo Omega, and are intended to foster overall health and wellness and potentially enhance the body's response to conditions such as stress, anxiety, restless sleep, inflammation and pain. These products feature PhytoCann Complex, a proprietary formulation consisting of non-psychoactive, plant-based bioactive compounds that support the body's endocannabinoid system.

07:15 EDT Orion Engineered moving to U.S. domestic filer status - Orion Engineered Carbons announced that the company will for all its SEC filings from January 1, 2020 onwards become a U.S. Domestic Filer and will thus file its 2019 Annual report as such. Orion thereby ends its Foreign Private Issuer status under Rule 3b-4(c) of the Securities Exchange Act of 1934.

07:14 EDT Pluristem CEO expects interim data readout for PLX-PAD in limb ischemia in 1H20 - Pluristem Therapeutics issued an update to its shareholders from its CEO Yaky Yanay, which read in part, "I would like to provide a brief update on the status of our development programs. These programs are the key elements in transforming Pluristem into a mature, profitable company that we believe will generate significant long-term value...PLX-R18 for acute radiation syndrome: Among our near-term priorities is to secure an agreement with the U.S. government this year. We developed this unique, lifesaving product candidate with the support of the U.S. National Institute of Allergy and Infectious Diseases, During the past year, we have completed a series of required studies and I intend to closely work with the agencies to satisfy the remaining development steps in order to bring to market this important product that can improve civilian and armed forces safety and preparedness. In parallel, we continue to work with the U.S. Department of Defense on the development of this novel compound as a countermeasure for ARS, prior to exposure to radiation. A series of studies conducted by the DoD was recently completed and I expect to be able to share the data with you in the coming weeks. PLX-PAD for critical limb ischemia: We are working hard to prepare the company for the interim data readout, which we expect in the first half of 2020 that, if positive, could support an application for conditional marketing approval in Europe under the European Union's Adaptive Pathways Program. This program could allow us to enter the market and begin generating revenue sooner than anticipated, which would be a true inflection point for our company. We also seek to advance our U.S. Food and Drug Administration's expanded access program, which could provide us with meaningful real-world data and potential cost recovery. PLX-PAD for muscle regeneration following hip fracture: We are advancing a multinational Phase III study and expect data in the second half of 2020. Today, there is no suitable medical treatment for the regeneration of damaged muscle and we see many reports that suggest up to 30% of hip fracture patients die within one year following the fracture due to immobility associated with the disease. This makes PLX-PAD a much-needed treatment which could potentially improve patients' lives while also saving hospitalization and rehabilitation costs. This important program also provided us with the opportunity to collaborate with NASA and examine our cells' ability to support muscle regeneration in the challenging microgravity environment which causes muscle and bone loss."

07:10 EDT Rexford Industrial announces update on ATM stock offering program - Rexford Industrial announced that, under its at the market, or ATM stock offering program, the company issued an aggregate of 5,669,424 shares of common stock during the quarter ending June 30. The shares were issued at a weighted average offering price of $38.21 per share, receiving gross proceeds of approximately $216.6M and net proceeds of approximately $213.4M. The company used the net proceeds of the ATM to fund acquisitions, for working capital and other general corporate purposes.

07:07 EDT Entera Bio initiates Phase 2 dose ranging study for Oral PTH - Entera Bio announced that it has initiated a Phase 2 study with its osteoporosis drug candidate EB613, an oral human PTH tablet. This double blinded, placebo controlled, dose-ranging study will evaluate three different doses in postmenopausal women with low bone mass. The study will include up to 160 patients dosed once daily for a period of 6 months. Human PTH is a known anabolic treatment currently available as a daily subcutaneous injection, Forteo with a known effect on bone formation biomarkers and bone mineral density. The primary endpoint of this study will be bone formation biomarkers at 3 months with an additional evaluation at 6 months, along with a BMD readout. The purpose of the study is to optimize the design of Entera's planned Phase 3 pivotal study, which Entera will explore performing with a larger pharmaceutical partner. The study was approved by the Israeli Ministry of Health and will be conducted at the osteoporosis clinics of 4 leading medical centers in Israel. These clinics have participated in a number of multinational osteoporosis trials for large pharmaceutical companies. All lab tests will be processed by an accredited central lab and BMD measurements will be monitored and analyzed in the US by a leading US CRO. The 3-month biomarker results are expected to provide preliminary insight into the efficacy of the oral PTH treatments and preliminary results may be obtained once the first half of the study population has been dosed for this period. A full study report will be generated upon completion of the 6-month biomarker and BMD analysis. It should be noted that preparations for the EB613 Phase 3 study are likely to commence after reviewing the 3-month biomarker data. The Company has already created a Phase 3 study outline and currently envisages a trial with a partner comparing EB613 to Forteo, enrolling 600 to 800 patients and with a primary endpoint based on non-inferiority in BMD outcome. Other details, including the EB613 dose and the length of the study, would be finalized based on the results obtained from the Phase 2 study.

07:04 EDT Premier begins supplying cysteine hydrochloride injection to providers - Premier, through its ProvideGx program, is now supplying cysteine hydrochloride injection to providers, a critical drug for pediatric and adult patients that require total parenteral nutrition, or TPN. Cysteine hydrochloride has been in shortage in the U.S. since 2015. This FDA-approved New Drug Application for cysteine hydrochloride injection is held by Exela Pharma Science. The financial terms of Premier's agreement for cysteine hydrochloride were not disclosed. Revenues from this agreement are not expected to materially impact Premier FY 2019 results.

06:53 EDT Endeavour Silver reports fatal accident at Bolanitos mine - Endeavour Silver announces with great sadness that a valued employee lost his life in a fatal accident at the Bolanitos mine in Guanajuato, Mexico on Saturday June 29. Jose de Jesus Morales Yebra, age 22, was working as a driller's helper with a senior driller installing roof bolts in the Plateros section of the mine when a part of the roof collapsed. Jose Morales was killed by falling rock. The driller also suffered minor injuries in the accident. Endeavour personnel immediately followed mine rescue protocols to close the mine, rescue the injured, inform the family and authorities and conduct a detailed investigation. The company extends its condolences and is taking care of the family in this time of need. The company emphasizes safety as the top priority in its mining operations. The investigation conclusions and recommendations will be reviewed with key mine-site management and workers at each of Endeavour Silver's operations this week by Endeavour's Vice President of Operations in order to better understand what more can be done to improve safety performance.

06:34 EDT UMBA announces agreement with Acordia and affiliate of Ares Management - The UMass Building Authority, or UMBA, announced that it has entered into definitive documents with Accordia Partners and an affiliate of the Real Estate Group of Ares Management on lease terms for the 20-acre site that had previously housed the Bayside Expo Center. Final lease terms for the site formalize an agreement in principle announced by the parties in February when UMBA voted to designate Accordia Partners and Ares to build a mixed-use urban innovation campus at the site. The proposed mixed-use project will consist of up to 3.4M square feet on the parcel. Under the terms of the agreement with UMBA, Accordia Partners and Ares will enter into a 99-year ground lease with expected consideration of $235M. Closing of the transaction and exchange of funds is expected to happen after Accordia and Ares receive all necessary regulatory approvals, which is expected to take approximately 24 months.

06:30 EDT Amarin sees Vascepa sales growth accelerating after label expansion - Amarin CEO John Thero said in this morning's press release, "We are pleased with the progress made to date, including the significant revenue growth we've achieved for Vascepa. We anticipate Vascepa revenue growth to accelerate further after label expansion approval and with a larger sales team, and then again after we commence promotion of Vascepa for cardiovascular risk reduction on television and through other media. We are preparing for a robust launch of REDUCE-IT data with the aim of helping physicians improve patient care for millions of patients with residual cardiovascular risk after their cholesterol is controlled, as identified by elevated triglycerides."

06:27 EDT Amarin jumps 6.5% to $20.50 after increasing 2019 sales outlook

06:12 EDT Amazon to create 1,000 new permanent jobs in Italy by end of 2019 - Amazon announced that it will create 1,000 permanent jobs in Italy by the end of 2019, in a move that will take the company's total workforce to over 6,500. These new job opportunities are for people with all types of experience, education and skill levels - from engineers and software developers, to logistics and marketing experts. Many new roles will also be available at Amazon's new fulfillment center that opened yesterday in Torrazza Piemonte and at its Delivery Stations across the country. Additional roles will be available at Amazon's existing fulfillment centers in Castel San Giovanni, Passo Corese and Vercelli, at its sortation center in Casirate d'Adda, at its Customer Service center in Cagliari, and at the company's corporate offices in Milan, the company said in a statement.

05:59 EDT KBR awarded $45.9M task order by NAVAIR - KBR announced that it has been awarded a $45.9M task order to provide logistics information technology services to the Naval Air Systems Command's, or NAVAIR, Logistics and Maintenance Information Systems and Technology Division. KBR was awarded this cost-plus-fixed-fee task order under the Department of Defense Information Analysis Center's, or DoD IAC, multiple-award contract, or MAC. The task order is part of the DoD IAC's Cyber Security and Information Systems Technical Area Task, or CSTAT. This task order was awarded by the U.S. Air Force Installation Contracting Center (AFICC). KBR won a seat on the CSTAT contract in December 2015.